Cholesterol Management in General Practice

References

• The Aspire Steering Group. ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). Heart 1996; 75: 334–3421. The Aspire Steering Group. ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). Heart 1996; 75: 334–342
   PubMed Web of Science ®Google Scholar
• Braunwald E, Sacks F M, Moye L A, Pfeiffer M A, Rouleau J L, Rutherford J D, Cole T G, Brown L, Warnica J W, Arnold J M, Wun C C, Davis B R. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. New Engl. J. Med. 1996; 335(14)1001–10092. Braunwald E, Sacks F M, Moye L A, Pfeiffer M A, Rouleau J L, Rutherford J D, Cole T G, Brown L, Warnica J W, Arnold J M, Wun C C, Davis B R. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. New Engl. J. Med. 1996; 335(14)1001–1009
   PubMed Web of Science ®Google Scholar
• Byington R P, Furberg C D, Crouse J R, III, Bond M G, Espeland M A. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am. J. Cardiol. 1995; 76: 54C–59C3. Byington R P, Furberg C D, Crouse J R, III, Bond M G, Espeland M A. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am. J. Cardiol. 1995; 76: 54C–59C
   PubMed Web of Science ®Google Scholar
• Byington R P, Jukema J W, Salonen J T, Pitt B, Bruschke A V, Hoen H, Furberg C D, Mancini G B. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the pravastatin atherosclerosis intervention program. Circulation 1995; 92: 2419–24254. Byington R P, Jukema J W, Salonen J T, Pitt B, Bruschke A V, Hoen H, Furberg C D, Mancini G B. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the pravastatin atherosclerosis intervention program. Circulation 1995; 92: 2419–2425
   PubMed Web of Science ®Google Scholar
• Cajraj H, Jamieson C W. A review. Coronary artery disease in patients with peripheral vascular disease. Brit. J. Surg. 1994; 81: 333–3425. Cajraj H, Jamieson C W. A review. Coronary artery disease in patients with peripheral vascular disease. Brit. J. Surg. 1994; 81: 333–342
   PubMed Web of Science ®Google Scholar
• Carroll M, Sempos C, Briefel R, Gray S, Johnson C. Serum lipids of adults 20–74yrs: United States 1976–80. Series 11: Data from the National Health Survey. Vital Health Stat. 1993; 242: 1–1076. Carroll M, Sempos C, Briefel R, Gray S, Johnson C. Serum lipids of adults 20–74yrs: United States 1976–80. Series 11: Data from the National Health Survey. Vital Health Stat. 1993; 242: 1–107
   Google Scholar
• Dayton S, Pearce M L, Hashimoto S, Dixon W J, Tomiyasu U. A controlled clinical trial of a diet high in unsaturated fat in preventing complications of atherosclerosis. Circulation 1969; 39–40(Suppl II)1–637. Dayton S, Pearce M L, Hashimoto S, Dixon W J, Tomiyasu U. A controlled clinical trial of a diet high in unsaturated fat in preventing complications of atherosclerosis. Circulation 1969; 39–40(Suppl II)1–63
   Google Scholar
• Durrington P N. Secondary hyperlipidaemia. Hyperlipidaemia, 2nd edn. Butterworth-Heinemann, Oxford 1995; 293–3088. Durrington P N. Secondary hyperlipidaemia. Hyperlipidaemia, 2nd edn. Butterworth-Heinemann, Oxford 1995; 293–308
   Google Scholar
• Frick M H, Elo O, Haapa K, Heinonen O P, Heinsalmi P, Huttunen J K, Kaitaniemi P, Koshinen P, Manninen V. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle aged men with dyslipidaemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. New Engl. J. Med. 1987; 317(20)1237–12459. Frick M H, Elo O, Haapa K, Heinonen O P, Heinsalmi P, Huttunen J K, Kaitaniemi P, Koshinen P, Manninen V. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle aged men with dyslipidaemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. New Engl. J. Med. 1987; 317(20)1237–1245
   PubMed Web of Science ®Google Scholar
• Furberg C D, Adams H P, Applegate W B, Byington R P, Espeland M A, Hartwell T, Hunninghake D B, Lefkowitz D S, Probstfield J, Riley W A. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 1994; 90: 1679–168710. Furberg C D, Adams H P, Applegate W B, Byington R P, Espeland M A, Hartwell T, Hunninghake D B, Lefkowitz D S, Probstfield J, Riley W A. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 1994; 90: 1679–1687
   PubMed Web of Science ®Google Scholar
• Haq I U, Yeo W W, Jackson P R, Ramsey L E. Should cholesterol be measured in all hypertensives?. J. Hum. Hypertens. 1995; 9: 417–42111. Haq I U, Yeo W W, Jackson P R, Ramsey L E. Should cholesterol be measured in all hypertensives?. J. Hum. Hypertens. 1995; 9: 417–421
   PubMed Web of Science ®Google Scholar
• Hertzer N R, Beven E G, Young J R, O'Hara P J, Ruschhaupt W F, Graor R A, Dewolfe V G, Maljovec L C. Coronary artery disease in peripheral vascular patients. A classification of 1000 angiograms and results of surgical management. Ann. Surg. 1984; 199: 223–23312. Hertzer N R, Beven E G, Young J R, O'Hara P J, Ruschhaupt W F, Graor R A, Dewolfe V G, Maljovec L C. Coronary artery disease in peripheral vascular patients. A classification of 1000 angiograms and results of surgical management. Ann. Surg. 1984; 199: 223–233
   PubMed Web of Science ®Google Scholar
• Lipid Research Clinics Program. The Lipid Research Clinics coronary primary prevention trial results. JAMA 1984; 251: 351–37413. Lipid Research Clinics Program. The Lipid Research Clinics coronary primary prevention trial results. JAMA 1984; 251: 351–374
   PubMed Web of Science ®Google Scholar
• Neaton J D, Blackburn H, Jacobs D, Kuller L, Lee D J, Sherwin R, Shih J, Wentworth D. Serum cholesterol level and mortality findings for men screened in MRFIT. Arch. Int. Med. 1992; 152: 1490–150014. Neaton J D, Blackburn H, Jacobs D, Kuller L, Lee D J, Sherwin R, Shih J, Wentworth D. Serum cholesterol level and mortality findings for men screened in MRFIT. Arch. Int. Med. 1992; 152: 1490–1500
   PubMed Web of Science ®Google Scholar
• OPCS study for the Department of Health and Ministry of Agriculture, Fisheries and Food. Blood lipid levels in the UK 199015. OPCS study for the Department of Health and Ministry of Agriculture, Fisheries and Food. Blood lipid levels in the UK 1990
   Google Scholar
• Pharoah P DP, Hollingworth W. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population. BMJ 1996; 312: 1443–144816. Pharoah P DP, Hollingworth W. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population. BMJ 1996; 312: 1443–1448
   PubMed Web of Science ®Google Scholar
• Royal College of General Practitioners. Guidelines for the management of hyperlipidaemia in general practice. Towards the primary prevention of coronary heart disease. The Royal College of General Practitioners, London 1992; 1–15, Occasional Paper 5517. Royal College of General Practitioners. Guidelines for the management of hyperlipidaemia in general practice. Towards the primary prevention of coronary heart disease. The Royal College of General Practitioners, London 1992; 1–15, Occasional Paper 55
   Google Scholar
• Rubin S M, Sidney S, Black D M, Browner W S, Hulley S B, Cummings S R. High blood cholesterol in elderly men and the excess risk for coronary heart disease. Ann. Intern. Med. 1990; 113: 916–92018. Rubin S M, Sidney S, Black D M, Browner W S, Hulley S B, Cummings S R. High blood cholesterol in elderly men and the excess risk for coronary heart disease. Ann. Intern. Med. 1990; 113: 916–920
   PubMed Web of Science ®Google Scholar
• Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4s). Lancet 1994; 344: 1383–138919. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4s). Lancet 1994; 344: 1383–1389
   PubMed Web of Science ®Google Scholar
• Thelle D S, Shaper A G, Whitehead T P, Bullock D G, Ashby D, Patel I. Blood lipids in middle aged British men. Brit. Heart. J. 1983; 49: 205–21320. Thelle D S, Shaper A G, Whitehead T P, Bullock D G, Ashby D, Patel I. Blood lipids in middle aged British men. Brit. Heart. J. 1983; 49: 205–213
   PubMedGoogle Scholar
• The West of Scotland Coronary Prevention Study Group. WOSCOPS. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N. Engl. J. Med. 1995; 333: 1301–130721. The West of Scotland Coronary Prevention Study Group. WOSCOPS. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N. Engl. J. Med. 1995; 333: 1301–1307
   PubMed Web of Science ®Google Scholar
• Working Group on Management of Patients with Hypertension and High Blood Cholesterol. National Education Program's Working Group report on the management of patients with hypertension and high blood pressure. Annals. Int. Med. 1991; 114: 224–23722. Working Group on Management of Patients with Hypertension and High Blood Cholesterol. National Education Program's Working Group report on the management of patients with hypertension and high blood pressure. Annals. Int. Med. 1991; 114: 224–237
   PubMed Web of Science ®Google Scholar